BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richardson PG, Zweegman S, O’donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S. Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy 2018;19:1949-68. [DOI: 10.1080/14656566.2018.1528229] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Šterman A, Sosič I, Časar Z. Primary trifluoroborate-iminiums enable facile access to chiral α-aminoboronic acids via Ru-catalyzed asymmetric hydrogenation and simple hydrolysis of the trifluoroborate moiety. Chem Sci 2022;13:2946-53. [PMID: 35432849 DOI: 10.1039/d1sc07065g] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cao Y, Tu Y, Fu L, Yu Q, Gao L, Zhang M, Zeng L, Zhang C, Shao J, Zhu H, Zhou Y, Li J, Zhang J. Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment. Eur J Med Chem 2022;233:114211. [PMID: 35218994 DOI: 10.1016/j.ejmech.2022.114211] [Reference Citation Analysis]
3 Cummins NW, Baker J, Chakraborty R, Dean PG, Garcia-Rivera E, Krogman A, Kumar S, Kuzmichev YV, Laird GM, Landay A, Lichterfeld M, Mahmood M, Martinson J, Maynes M, Natesampillai S, Rajkumar V, Rassadkina Y, Ritter KD, Rivera CG, Rizza SA, Subramanian K, Tande AJ, Wonderlich ER, Whitaker JA, Zeuli J, Badley AD. Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. EClinicalMedicine 2021;42:101225. [PMID: 34901797 DOI: 10.1016/j.eclinm.2021.101225] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Jayaweera SPE, Wanigasinghe Kanakanamge SP, Rajalingam D, Silva GN. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Front Oncol 2021;11:740796. [PMID: 34858819 DOI: 10.3389/fonc.2021.740796] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
5 Tripathi BK, Anderman MF, Bhargava D, Boccuzzi L, Qian X, Wang D, Durkin ME, Papageorge AG, de Miguel FJ, Politi K, Walters KJ, Doroshow JH, Lowy DR. Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein. Nat Commun 2021;12:6941. [PMID: 34862367 DOI: 10.1038/s41467-021-26993-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Song S, Gao P, Sun L, Kang D, Kongsted J, Poongavanam V, Zhan P, Liu X. Recent developments in the medicinal chemistry of single boron atom-containing compounds. Acta Pharm Sin B 2021;11:3035-59. [PMID: 34729302 DOI: 10.1016/j.apsb.2021.01.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
7 Sampat PJ, Bisen M, Srivastava N, Rao S, Gentile T. Accidental Ixazomib Overdose in a Patient With Multiple Myeloma. J Investig Med High Impact Case Rep 2021;9:23247096211013230. [PMID: 33980053 DOI: 10.1177/23247096211013230] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Guo M, Ding P, Zhu Z, Fan L, Zhou Y, Yang S, Yang Y, Gu C. Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma. Front Cell Dev Biol 2021;9:675939. [PMID: 33968945 DOI: 10.3389/fcell.2021.675939] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Liang X, Wu P, Yang Q, Xie Y, He C, Yin L, Yin Z, Yue G, Zou Y, Li L, Song X, Lv C, Zhang W, Jing B. An update of new small-molecule anticancer drugs approved from 2015 to 2020. Eur J Med Chem 2021;220:113473. [PMID: 33906047 DOI: 10.1016/j.ejmech.2021.113473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dunphy K, Dowling P, Bazou D, O'Gorman P. Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers. Cancers (Basel) 2021;13:1930. [PMID: 33923680 DOI: 10.3390/cancers13081930] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
11 Cespedes DA, Gallitano SM, Bhutani D. Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma. Ann Hematol 2021. [PMID: 33860355 DOI: 10.1007/s00277-021-04524-w] [Reference Citation Analysis]
12 Liu JR, Li J, Huang XJ. [Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2021;42:82-6. [PMID: 33677876 DOI: 10.3760/cma.j.issn.0253-2727.2021.01.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Harousseau JL, Mohty M. Up-front ixazomib in older patients with myeloma. Blood 2021;137:3584-6. [PMID: 34196682 DOI: 10.1182/blood.2021011262] [Reference Citation Analysis]
14 Roeten MSF, van Meerloo J, Kwidama ZJ, Ter Huizen G, Segerink WH, Zweegman S, Kaspers GJL, Jansen G, Cloos J. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells 2021;10:665. [PMID: 33802801 DOI: 10.3390/cells10030665] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Soysouvanh F, Giuliano S, Habel N, El-Hachem N, Pisibon C, Bertolotto C, Ballotti R. An Update on the Role of Ubiquitination in Melanoma Development and Therapies. J Clin Med 2021;10:1133. [PMID: 33800394 DOI: 10.3390/jcm10051133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang Q, Dong Z, Su J, Huang J, Xiao P, Tian L, Chen Y, Ma L, Chen X. Ixazomib inhibits myeloma cell proliferation by targeting UBE2K. Biochem Biophys Res Commun 2021;549:1-7. [PMID: 33647537 DOI: 10.1016/j.bbrc.2021.02.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Lemoine J, Bonnin A, Marjanovic Z, van de Wyngaert Z, Ikhlef S, Alsuliman T, M'Hammedi-Bouzina F, Mohty M, Malard F. Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. Curr Res Transl Med 2021;69:103283. [PMID: 33639586 DOI: 10.1016/j.retram.2021.103283] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Gu Y, Barwick BG, Shanmugam M, Hofmeister CC, Kaufman J, Nooka A, Gupta V, Dhodapkar M, Boise LH, Lonial S. Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J 2020;10:125. [PMID: 33318477 DOI: 10.1038/s41408-020-00393-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac J Clin Oncol 2021;17:29-35. [PMID: 32920949 DOI: 10.1111/ajco.13459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yang J, Li D, Zhou J. Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies. Front Pharmacol 2020;11:971. [PMID: 32676030 DOI: 10.3389/fphar.2020.00971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A, Rajalingam K, Chantry AD, Irvine AE. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene 2020;39:5001-14. [PMID: 32523091 DOI: 10.1038/s41388-020-1345-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
22 Dash AB, Zhang J, Shen L, Li B, Berg D, Lin J, Avet-Loiseau H, Bahlis NJ, Moreau P, Richardson PG, Di Bacco A. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation. Eur J Haematol 2020;105:274-85. [PMID: 32350909 DOI: 10.1111/ejh.13435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Sánchez G, Chalmers S, Ahumada X, Montecinos L, Olmedo I, Eisner V, Riveros A, Kogan MJ, Lavandero S, Pedrozo Z, Donoso P. Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia. PLoS One 2020;15:e0233591. [PMID: 32453773 DOI: 10.1371/journal.pone.0233591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther 2020;213:107579. [PMID: 32442437 DOI: 10.1016/j.pharmthera.2020.107579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
25 Harris MA, Miles MA, Shekhar TM, Cerra C, Georgy SR, Ryan SD, Cannon CM, Hawkins CJ. The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice. Cancers (Basel) 2020;12:E1207. [PMID: 32403415 DOI: 10.3390/cancers12051207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lai KP, Chen J, Tse WKF. Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy. Int J Mol Sci 2020;21:E2548. [PMID: 32268558 DOI: 10.3390/ijms21072548] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
27 Alanazi F, Kwa FAA, Burchall G, Jackson DE. New generation drugs for treatment of multiple myeloma. Drug Discov Today 2020;25:367-79. [PMID: 31765717 DOI: 10.1016/j.drudis.2019.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
28 Nicolaou KC, Rigol S. The Role of Organic Synthesis in the Emergence and Development of Antibody–Drug Conjugates as Targeted Cancer Therapies. Angew Chem Int Ed 2019;58:11206-41. [DOI: 10.1002/anie.201903498] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 12.3] [Reference Citation Analysis]
29 Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan D. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia 2019;33:2685-94. [PMID: 30962579 DOI: 10.1038/s41375-019-0467-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]